2001

Genetrix was founded as a spin-off from the National Center of Biotechnology (CNB) located in the Madrid Science Park (PCM).

2002

The Group creates cellular and molecular lines of research:  New HQ is established at  Marconi 1 in the Madrid Technology Park (PTM) located in Tres Cantos with an area of 1000 m2, of which 670 m2 is devoted to Research and Development.

2003

A “NEOTEC” loan for €.0.3 million is obtained from the Center for the Development of Industrial Technology (CDTI)

2004

Genetrix closes a €9 million funding round and creates a new company “Cellerix” from its cellular research:

Creation of Cellerix

• 2004
  - Closes a financing round worth €1.3 million led by Genetrix and the Management Team.
  - The Phase II clinical trial with Ontaril® for treatment of complex perianal fistulas starts.
  
• 2005
  - Closes a financing round worth €4.3 million led by Genetrix and private investors.
  - Orphan drug designation for Ontaril® by The European Medicines Agency (EMEA).
  - Investigations for developing a chimeric skin indicated for treatment of Epidermolysis Bullosa (Cx501) start.
  
• 2006
  - The Phase II clinical trial with Ontaril® is successfully complete.
  - Orphan drug designation by The European Medicines Agency (EMEA) for Cx501 is granted.
  
• 2007
  - Cellerix closes a financing round worth €27.2 million led by international and national partners, Corporate Venture Funds and other financial investors include existing shareholders (Genetrix and Nerel).
  - The Phase III clinical trial with Ontaril® starts.
  - Cellerix concludes a licensing agreement with Axcan Pharma Inc. to co-develop and marketing Ontaril in North America, Mexico and Canada worth up to €28 million.
  - The Phase I/II clinical trial for Cx501 starts.
  - First preclinical research to develop a wide range of medicines indicated for the treatment of inflammatory diseases (Cx611) starts.
• 2008
  - Cellerix obtain a 10M€ debt facility with ETV Capital.
• 2009
  - Cellerix names board member Eduard E Holdener.

2005

Genetrix receives prize for "Technology-Based Firm" from the Tres Cantos City Council
Genetrix closes a financing round worth €6.3 million.
Genetrix makes a financial contribution of 8% in shareholding Bioalma.

Genetrix founds a new company from its molecular research called Biotherapix Molecular Medicine:

• 2005
  - Launch of platform for generation and screening human monoclonal antibodies with therapeutic and diagnostic applications
  - New research focused on new generation anti-inflammatory drugs - specifically chemokine receptor antagonists (Diakines ®) starts.
• 2006
  - Biotherapix sets up new laboratory of 250 m2 in the Madrid Science Park (PCM)

Genetrix founds Imbiosis in collaboration with the gluten unit of CNB - dedicated to detection and removal of gluten from foods.

• 2005
  - Exclusive licensing agreement signed for marketing of "Cocktail" solution developed by the CNB for extraction of gluten.
• 2006
  -Imbiosis makes its first profit and secures customers such as Hero, Kelloggs, Matutano, Polar, Chamtor, Cerestar, Raisio
  
• 2007
  - Customer base grows with the addition of Cueto & Mercadona.
  - Imbiosis reaches 5,000 samples processed in 60 types of food
  

Genetrix founds Sensia S.L - dedicated to development of biosensors to detect compounds for life sciences laboratories and environmental monitoring.

• 2006
  - Sensia develops a prototype biosensor based on the Surface Plasmon Resonance (SPR) technology.
• 2007
  - The Mondragon group enters as a Sensia shareholder.
  - Sensia closes financing round worth €0.3 million.
• 2008
  - A CDTI loan is obtained for 0,4 M€.
• 2009
  - Sensia will make the commercial version of a functional and mobile commercial prototype that can detect and quantify substances (e.g. THG) available last quarter of 2009.

2006

Genetrix closes financing round worth €0.3 million and creates Coretherapix focused on regenerative cardiac medicine.

Genetrix founds Biobide, the first Spanish company to focus on massively automated testing of new drugs using zebrafish.

• 2007
  - Biobide becomes the European platform for HTS in zebrafish with a capacity for analyzing up to 5,000 compounds per day.
  - Biobide closes its first agreement for testing of new drugs with a pharmaceutical company.
• 2008
  - Biobide has achieved the certificate as a laboratory Good Manufacturing Practice (GMP).
• 2009
  - Biobide wins Bio BUZZ in the Bio International Convention of Atlanta.

2007

Coretherapix foundation

• 2007
  - Coretherapix begins pre-clinical research to develop cellular products indicated for chronic heart failure.
• 2008
  - Coretherapix is part of the CAREMI (Cardio Repair European Multidisciplinary Initiative) consortium funded by European Comission. (Seventh Framework Programme (FP7).

Fenix Biotech foundation, as a Joint Venture between Genetrix and Advancell.

• 2007
  - Fenix Biotech begins pre-clinical research to develop cellular products indicated for monogenic diseases.

2008

Genetrix founds X-Pol Biotech - focusing on polymerases for DNA repair and improved amplification.

• 2008
  - May: Foundation of X-Pol Biotech as a company focusing on polymerases for DNA repair and improved amplification.
  - June: X-Pol laboratories are established in the Madrid Science Park (PCM).
  - July: X-Pol Biotech starts its activities with 5 employes in the company.
  
• 2009
  - June: Prof. Aidan Doherty, new member of X-Pol.
  - July: 7 employees in the company.